Coherus Oncology (CHRS) Other Working Capital Changes (2013 - 2026)

Coherus Oncology (CHRS) has 11 years of Other Working Capital Changes data on file, last reported at $468000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes fell 45.45% year-over-year to $468000.0; the trailing twelve-month figure through Mar 2026 stood at -$10.7 million (down 2114.46% YoY), and the FY2025 full-year result was -$10.3 million, down 12695.12% from the prior year.
• Other Working Capital Changes eased to $468000.0 in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $7.6 million in Q1 2022 to a low of -$5.9 million in Q3 2023.
• A 5-year average of -$211411.8 and a median of -$1.4 million in 2022 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes jumped 1203.88% in 2024 and sank 3352.17% in 2025, its largest moves.
• Tracing CHRS's Other Working Capital Changes over 4 years: stood at -$5.0 million in 2023, then surged by 124.25% to $1.2 million in 2024, then jumped by 90.84% to $2.3 million in 2025, then plunged by 79.77% to $468000.0 in 2026.
• Business Quant data shows CHRS's Other Working Capital Changes at $468000.0 in Q1 2026, $2.3 million in Q4 2025, and -$23.2 million in Q3 2025.